Nurix Therapeutics, Inc. Common stock Earnings Dividend

Nurix Therapeutics, Inc. Common stock’s revenue fell -79.47% since last year same period to $9.04Mn in the Q2 2026. On a quarterly growth basis, Nurix Therapeutics, Inc. Common stock has generated 44.64% jump in its revenue since last 3-months.

Nurix Therapeutics, Inc. Common stock’s net profit fell -106% since last year same period to $-89.54Mn in the Q2 2026. On a quarterly growth basis, Nurix Therapeutics, Inc. Common stock has generated -2.71% fall in its net profits since last 3-months.

Nurix Therapeutics, Inc. Common stock’s net profit margin fell -903.59% since last year same period to -990.1% in the Q2 2026. On a quarterly growth basis, Nurix Therapeutics, Inc. Common stock has generated 28.99% jump in its net profit margins since last 3-months.

Nurix Therapeutics, Inc. Common stock’s earning per share (EPS) estimates for the current quarter stand at -0.56 - a 23.29% jump from last quarter’s estimates.

Nurix Therapeutics, Inc. Common stock’s earning per share (EPS) estimates for the current year stand at -0.56.

Nurix Therapeutics, Inc. Common stock’s earning per share (EPS) fell -55.77% since last year same period to -0.81 in the Q2 2026. This indicates that the Nurix Therapeutics, Inc. Common stock has generated -55.77% annual rate of fall in its earning per share (EPS) in the last 4 quarters.